{"preliminary_commentary":{"by_channel":{"youtube":8,"podcast":6,"x_thread":2,"bluesky_thread":2},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04173533\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"AMADEUS","nct_id":"NCT04173533","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=amadeus-nct04173533. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"AMADEUS","arms":[{"description":"Oral azacitidine (CC-486) matched placebo once daily for first 14 days of each 28 day cycle","label":"Control Group","type":"PLACEBO_COMPARATOR"},{"description":"Oral azacitidine (CC-486) 200 mg once daily for first 14 days of each 28 day cycle","label":"Experimental Group","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2026-04-29","type":"ACTUAL"},"conditions":["Acute Myeloid Leukemia","Myelodysplasia"],"enrollment":{"count":326,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Oral azacitidine","otherNames":["CC-486"],"type":"DRUG"},{"name":"Matched placebo","otherNames":["Oral azacitidine matched placebo"],"type":"DRUG"}],"last_update":"2026-08-14","lead_sponsor":"University of Birmingham","official_title":"A Double-Blind, Phase III, Randomised Study to Compare the Efficacy and Safety of Oral Azacitidine (CC-486) Versus Placebo in Subjects With Acute Myeloid Leukaemia or Myelodysplastic Syndromes as Maintenance After Allogeneic Haematopoietic Stem Cell Transplantation","overall_status":"COMPLETED","phases":["PHASE3"],"primary_completion_date":{"date":"2026-04-29","type":"ACTUAL"},"primary_outcomes":[{"measure":"Relapse free survival (RFS)","timeFrame":"12 months"}],"references":[],"start_date":{"date":"2019-06-14","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Randomised Study of Oral Azacitidine vs Placebo Maintenance in AML or MDS Patients After Allo-SCT","url":"https://clinicaltrials.gov/study/NCT04173533"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/amadeus-nct04173533"}